Ensysce Biosciences, Inc. (ENSC) Key Statistics & Financial Ratios

Ensysce Biosciences, Inc. (ENSC) — Price $0.45 — Healthcare — Biotechnology — NASDAQ

Latest reported results:

Key statistics dashboard for Ensysce Biosciences, Inc. (ENSC). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose.

Stock Data

Price$0.45
Market Cap$7M
Enterprise Value$6.4M
ExchangeNASDAQ
CountryUS

Valuation Multiples

P/E Ratio-0.16
Price / Book-7.53
P/S5.96
EV/EBITDA-0.51
EV/Sales5.50
EV/FCF-0.71
P/FCF-0.77
Earnings Yield-216.26%
FCF Yield-130.50%
Dividend Yield0.00%

Profitability

Gross Margin100.00%
EBIT Margin-1083.90%
EBITDA Margin-1083.34%
Operating Margin-1087.47%
Net Margin-1084.23%
Return on Equity-1532.33%
Return on Assets-426.88%
Return on Invested Capital1385.30%
Return on Capital Employed1139.82%

Financial Health

Current Ratio0.70
Quick Ratio0.70
Cash Ratio0.17
Debt / Equity-0.25
Debt / Assets6.66%
Net Debt / EBITDA0.04
Interest Coverage-791.64
Piotroski F-Score0
Altman Z-Score-29.36

Per-Share Data

Revenue per share0.09
Book Value per share-0.09
Cash per share0.05
FCF per share-0.69
Tangible Book Value per share-0.09
Dividend per share0.00

Analyst Consensus

Strong Buy0
Buy2
Hold0
Sell0
Strong Sell0
Total analysts2
Avg rating (1-5)1.00

Related companies: AIM · CANF · KALA · KZIA · OGEN · QLGN · SNGX

Explore sector: Healthcare · Biotechnology

More sections of ENSC: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks